Recommended Pages at xconomy.com
Antibiotic R&D is in Trouble: Here’s a Fix | Xconomy
xconomy.com — “Bacteria have been on Earth for more than a billion years, evolving in crafty ways to stay alive amid all kinds of threats. Only about 70 years ago, antibiotics” View full resource at xconomy.com
Most Recently Shared on May 7, 2012 at 2:23 pm By:
Luke Timmerman Health Communicator
Free Markets Are Failing Antibiotics: Here’s A Way to Fix Things | Xconomy http://t.co/s7M8437r
Virtual Biotech Companies: Built on Solid Bedrock or Unstable Landfill? | Xconomy
xconomy.com — “A recent meeting focused on “Reinventing Biotech’s Business Model” provided an interesting window into the spectrum of approaches being used to create new” View full resource at xconomy.com
Most Recently Shared on May 3, 2012 at 8:38 pm By:
Luke Timmerman Health Communicator
Virtual Biotech Companies: Built on Solid Bedrock or Unstable Landfill? Stewart Lyman guest post http://t.co/TvEXpc4u
Mersana Adds $4M For Next-Generation “Armed” Cancer Drugs | Xconomy
xconomy.com — “Cambridge, MA-based Mersana Therapeutics is working in one of the hottest areas of biotech research---it’s figuring out new ways to attach potent anti-cancer” View full resource at xconomy.com
Most Recently Shared on May 1, 2012 at 5:42 pm By:
Luke Timmerman Health Communicator
Mersana Adds $4M For Next-Generation “Armed” Cancer Drugs | Xconomy http://t.co/eEuLtOIc
Berwick’s Advice: Cost-Effectiveness Is Here to Stay | Xconomy
xconomy.com — “Dr. Donald Berwick, the former administrator of the Center for Medicare and Medicaid Services, held his post from July 2010 until December 2011 (about 18 months” View full resource at xconomy.com
Most Recently Shared on April 30, 2012 at 7:14 pm By:
Luke Timmerman Health Communicator
Berwick’s Advice: Cost-Effectiveness Is Here to Stay. Guest post by John Osborn http://t.co/0UtJfa5h
Hologic Buys Gen-Probe for $3.7B, Making Molecular Diagnostics Push | Xconomy
xconomy.com — “Hologic has made big-money acquisitions before, and today it’s making another sizable one. The Bedford, MA-based maker of women’s health products” View full resource at xconomy.com
Most Recently Shared on April 30, 2012 at 5:09 pm By:
Luke Timmerman Health Communicator
Hologic Buys Gen-Probe for $3.7B, Making Molecular Diagnostics Push | Xconomy http://t.co/V6nm1BDy
Biotech IPOs Start to Show Some Modest Signs of Life | Xconomy
xconomy.com — “Something feels wrong about putting the words “biotech” and “IPO” together in a headline. This market has been lifeless for so long that few investors” View full resource at xconomy.com
Most Recently Shared on April 30, 2012 at 1:32 pm By:
Luke Timmerman Health Communicator
Biotech IPOs Start to Show Some Modest Signs of Life | Xconomy http://t.co/sLYg73OS
Taking Open Biology to the Next Level: Notes from the Sage Congress | Xconomy
xconomy.com — “Last week, attendees of Sage Bionetworks’ 3rd Annual Congress came to San Francisco with the bold charge to speed up drug discovery and ready to stand on the” View full resource at xconomy.com
Most Recently Shared on April 27, 2012 at 6:17 pm By:
Luke Timmerman Health Communicator
Taking open biology to the next level: Guest @xconomy post by @sagebio founder Stephen Friend http://t.co/6TXT8oIL #sagecon
Big Data, Big Biology, and the ‘Tipping Point’ in Quantified Health | Xconomy
xconomy.com — “Two of the biggest trends in technology innovation are converging---and as they come together, there is a chance to accomplish something rare in San Diego.” View full resource at xconomy.com
Most Recently Shared on April 27, 2012 at 1:29 pm By:
Dr Steven Tucker Oncologist, Physician, Doctor, and Internist
Your Weekend Read | Big Data, Big Biology, and the ‘Tipping Point’ in Quantified Health http://t.co/l2Z3Bnga
UW Startups Look to Improve Bras, Bicycle Ads, Mental Health | Xconomy
xconomy.com — “The University of Washington campus is so big, with 42,000 students, that it’s impossible to get a handle on everything going on there. But this much I can” View full resource at xconomy.com
Most Recently Shared on April 26, 2012 at 5:46 pm By:
Luke Timmerman Health Communicator
UW startups look to improve bicycle ads, mental health, bras. http://t.co/0WPb4zGp
Cardeas Gears Up for Clinic, With Drug Combo for Hospital Infections | Xconomy
xconomy.com — “Once while reporting on a medical meeting for new antibiotics, I met a physician/researcher who said “stay in the hospital long enough, and something bad will” View full resource at xconomy.com
Most Recently Shared on April 26, 2012 at 3:43 pm By:
Luke Timmerman Health Communicator
Cardeas Gears Up for Clinic, With Drug Combo for Hospital Infections | Xconomy http://t.co/tWMdFE4x
Ad Tech Boom Continues With $1M Funding of Precision Health | Xconomy
xconomy.com — “Ever since Xconomy New York launched almost a year ago, we've been tracking the incredible rise of advertising technology startups in the city. Now we can add” View full resource at xconomy.com
Most Recently Shared on April 3, 2012 at 4:38 pm By:
Targeted Health Ads w/ Precision Health http://t.co/YnUp0FUt #phrma
Third Rock’s Mark Levin: ‘Ultra-Super Positive’ on Biotech Innovation | Xconomy
xconomy.com — “Mark Levin co-founded Boston's Third Rock Ventures in 2007 with the goal of funding life sciences discoveries through the Valley of Death---when early-stage” View full resource at xconomy.com
Most Recently Shared on March 29, 2012 at 2:56 pm By:
Luke Timmerman Health Communicator
Third Rock’s Mark Levin: ‘Ultra-Super Positive’ on Biotech Innovation | Xconomy http://t.co/mgNVrpR0
Accelerator Gets New Chief Scientist, David McElligott | Xconomy
xconomy.com — “The Accelerator, the place that starts more biotech companies than any other outfit in Seattle, has had a changing of the scientific guard. David McElligott,” View full resource at xconomy.com
Most Recently Shared on March 28, 2012 at 8:46 pm By:
Luke Timmerman Health Communicator
Seattle-based Accelerator gets new chief scientist, fmr Icos biologist David McElligott http://t.co/FxGy9rSI
Amylin Booms on Report it Rejected Bristol’s $3.5B Takeover Bid | Xconomy
xconomy.com — “San Diego-based Amylin Pharmaceuticals (NASDAQ: ]) saw its shares boom today after it reportedly turned down a $3.5 billion takeover bid from New York-based” View full resource at xconomy.com
Most Recently Shared on March 28, 2012 at 4:28 pm By:
Luke Timmerman Health Communicator
SD-based Amylin shares climb almost 50% on report it rejected Bristol bid. http://t.co/W10T5wEj
Affymax, Takeda Win Approval of Anemia Drug to Challenge Amgen | Xconomy
xconomy.com — “Affymax completed its surprising comeback today, as it won FDA clearance for its first marketed drug, a product for anemia that will be the first to rival a” View full resource at xconomy.com
Most Recently Shared on March 27, 2012 at 4:58 pm By:
Luke Timmerman Health Communicator
Update to Affymax FDA approval story, with comments from CEO John Orwin. Conf call coming later today. http://t.co/bG1ow9T0
